TY - JOUR
T1 - Disease- and Therapy-Specific impact on Humoral immune Responses to cOViD-19 Vaccination in Hematologic Malignancies
AU - Chung, David J.
AU - Shah, Gunjan L.
AU - Devlin, Sean M.
AU - Ramanathan, Lakshmi V.
AU - Doddi, Sital
AU - Pessin, Melissa S.
AU - Hoover, Elizabeth
AU - Marcello, Lee Ann T.
AU - Young, Jennifer C.
AU - Boutemine, Sawsan R.
AU - Serrano, Edith
AU - Sharan, Saumya
AU - Momotaj, Saddia
AU - Margetich, Lauren
AU - Bravo, Christina D.
AU - Papanicolaou, Genovefa A.
AU - Kamboj, Mini
AU - Mato, Anthony R.
AU - Roeker, Lindsey E.
AU - Hultcrantz, Malin
AU - Mailankody, Sham
AU - Lesokhin, Alexander M.
AU - Vardhana, Santosha A.
AU - Knorr, David A.
N1 - Publisher Copyright:
©2021 American Association for Cancer Research.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Coronavirus disease-19 (COVID-19) vaccine response data for patients with hematologic malignancy, who carry high risk for severe COVID-19 illness, are incomplete. In a study of 551 hematologic malignancy patients with leukemia, lymphoma, and multiple myeloma, anti–SARS-CoV-2 spike IgG titers and neutralizing activity were measured at 1 and 3 months from initial vaccination. Compared with healthy controls, patients with hematologic malignancy had attenuated antibody titers at 1 and 3 months. Furthermore, patients with hematologic malignancy had markedly diminished neutralizing capacity of 26.3% at 1 month and 43.6% at 3 months, despite positive seroconversion rates of 51.5% and 68.9% at the respective time points. Healthy controls had 93.2% and 100% neutralizing capacity at 1 and 3 months, respectively. Patients with leukemia, lymphoma, and multiple myeloma on observation had uniformly blunted responses. Treatment with Bruton tyrosine kinase inhibitors, venetoclax, phosphoinositide 3-kinase inhibitors, anti-CD19/CD20–directed therapies, and anti-CD38/B-cell maturation antigen–directed therapies substantially hindered responses, but single-agent immunomodulatory agents did not.
AB - Coronavirus disease-19 (COVID-19) vaccine response data for patients with hematologic malignancy, who carry high risk for severe COVID-19 illness, are incomplete. In a study of 551 hematologic malignancy patients with leukemia, lymphoma, and multiple myeloma, anti–SARS-CoV-2 spike IgG titers and neutralizing activity were measured at 1 and 3 months from initial vaccination. Compared with healthy controls, patients with hematologic malignancy had attenuated antibody titers at 1 and 3 months. Furthermore, patients with hematologic malignancy had markedly diminished neutralizing capacity of 26.3% at 1 month and 43.6% at 3 months, despite positive seroconversion rates of 51.5% and 68.9% at the respective time points. Healthy controls had 93.2% and 100% neutralizing capacity at 1 and 3 months, respectively. Patients with leukemia, lymphoma, and multiple myeloma on observation had uniformly blunted responses. Treatment with Bruton tyrosine kinase inhibitors, venetoclax, phosphoinositide 3-kinase inhibitors, anti-CD19/CD20–directed therapies, and anti-CD38/B-cell maturation antigen–directed therapies substantially hindered responses, but single-agent immunomodulatory agents did not.
UR - https://www.scopus.com/pages/publications/85122439443
U2 - 10.1158/2643-3230.BCD-21-0139
DO - 10.1158/2643-3230.BCD-21-0139
M3 - Article
C2 - 34778797
AN - SCOPUS:85122439443
SN - 2643-3230
VL - 2
SP - 568
EP - 576
JO - Blood cancer discovery
JF - Blood cancer discovery
IS - 6
ER -